Association Between Aspirin Use and Biliary Tract Cancer Survival
Open Access
- 1 December 2019
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 5 (12) , 1802-1804
Abstract
Biliary tract cancers (BTCs) are rare, with a worldwide incidence of less than 2 per 100 000 individuals.1 The 5-year survival rate ranges from 5% to 15%, with a median survival of less than 1 year.1 Between 60% and 70% of patients present with late-stage disease (eg, inoperable or metastatic tumors) owing to the lack of symptoms.2 Consequently, there is a critical need for treatments that improve BTC survival. Aspirin has been proposed as a treatment to reduce cancer mortality because it may slow cancer growth through the inhibition of both cyclooxygenase 2, which promotes inflammation and cell proliferation,3 and platelet aggregation, which may slow the metastatic spread of cancer.4 We investigated the association between postdiagnosis aspirin use and BTC survival.Keywords
This publication has 6 references indexed in Scilit:
- Adjusted Survival Curves Improve Understanding of Multivariable Cox Model ResultsThe Journal of Arthroplasty, 2021
- New Horizons for Precision Medicine in Biliary Tract CancersCancer Discovery, 2017
- Gallbladder cancer: epidemiology and outcomeClinical Epidemiology, 2014
- Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?British Journal of Cancer, 2011
- Contribution of platelets to tumour metastasisNature Reviews Cancer, 2011
- Role of plasma, platelets, and endothelial cells in tumor metastasisCancer and Metastasis Reviews, 1984